• Something wrong with this record ?

The role of cryopreservation techniques in manufacturing, transport, and storage of Car-T therapy products

M. Jandova, GN. Stacey, M. Lanska, I. Gregor, P. Rozsivalova, L. Bekova, ZW. Duchacova, D. Belada, J. Radocha, P. Mericka, B. Fuller

. 2023 ; 44 (3) : 123-133. [pub] -

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24001299

Several clinical trials have proved the efficacy and safety of T-cells chimeric antigen receptor (CAR-T cells) in treatment of malignant lymphoma and the first products were registered in the European Union in 2018. The shelf-life of CAR-T cell products in the liquid state is short, so cryopreservation offers a significant benefit for logistics in manufacturing and patient management. Direct shipment of the cryopreserved CAR-T cell therapy products to the clinical department is feasible, nevertheless, intermediate storage in the hospital cryostorage facility gives significant advantage in planning of their administration to patients. Moreover, some manufacturers prefer transport of the starting material cryopreserved at the collection site. The cryopreservation protocol used for starting material by the authors is based on combining dimethyl sulphoxide (DMSO) with hydroxyethyl starch (HES) and slow controlled cooling in cryobags housed in metal cassettes. This achieves the mononuclear cell post-thaw viability of 98.8 ± 0.5 % and recovery of 72.8, ± 10.2 %. Transport of the starting material to the manufactures and return transport of the CAR-T therapy product is performed by authorized courier companies. Intermediate cryostorage of the final CAR-T cell therapy product is performed in a separate dry-storage liquid nitrogen container. On the day of infusion, the cryopreserved products are transported to the clinical department in a dry shipper. On the wards the product is removed from the cassette, inserted into a sterile plastic bag, thawed in a 37 degree C water bath followed by immediate intravenous administration. The authors discuss the adherence of the used technology to good manufacturing practice (GMP) principles and genetic safety assurance rules. Doi: 10.54680/fr23310110112.

000      
00000naa a2200000 a 4500
001      
bmc24001299
003      
CZ-PrNML
005      
20240213094529.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
035    __
$a (PubMed)37883165
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jandova, M $u Tissue Bank, University Hospital Hradec Kralove; Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic. jandomir@fnhk.cz
245    14
$a The role of cryopreservation techniques in manufacturing, transport, and storage of Car-T therapy products / $c M. Jandova, GN. Stacey, M. Lanska, I. Gregor, P. Rozsivalova, L. Bekova, ZW. Duchacova, D. Belada, J. Radocha, P. Mericka, B. Fuller
520    9_
$a Several clinical trials have proved the efficacy and safety of T-cells chimeric antigen receptor (CAR-T cells) in treatment of malignant lymphoma and the first products were registered in the European Union in 2018. The shelf-life of CAR-T cell products in the liquid state is short, so cryopreservation offers a significant benefit for logistics in manufacturing and patient management. Direct shipment of the cryopreserved CAR-T cell therapy products to the clinical department is feasible, nevertheless, intermediate storage in the hospital cryostorage facility gives significant advantage in planning of their administration to patients. Moreover, some manufacturers prefer transport of the starting material cryopreserved at the collection site. The cryopreservation protocol used for starting material by the authors is based on combining dimethyl sulphoxide (DMSO) with hydroxyethyl starch (HES) and slow controlled cooling in cryobags housed in metal cassettes. This achieves the mononuclear cell post-thaw viability of 98.8 ± 0.5 % and recovery of 72.8, ± 10.2 %. Transport of the starting material to the manufactures and return transport of the CAR-T therapy product is performed by authorized courier companies. Intermediate cryostorage of the final CAR-T cell therapy product is performed in a separate dry-storage liquid nitrogen container. On the day of infusion, the cryopreserved products are transported to the clinical department in a dry shipper. On the wards the product is removed from the cassette, inserted into a sterile plastic bag, thawed in a 37 degree C water bath followed by immediate intravenous administration. The authors discuss the adherence of the used technology to good manufacturing practice (GMP) principles and genetic safety assurance rules. Doi: 10.54680/fr23310110112.
650    _2
$a lidé $7 D006801
650    12
$a chimerické antigenní receptory $x genetika $7 D000076962
650    _2
$a kryoprezervace $x metody $7 D015925
650    _2
$a imunoterapie adoptivní $x metody $7 D016219
650    _2
$a nízká teplota $7 D003080
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stacey, G N $u International Stem Cell Banking Initiative, 2 High Street, Barley, Herts, SG88HZ, UK. National Stem Cell Resource Centre, Institute of Zoology; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China
700    1_
$a Lanska, M $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Gregor, I $u Tissue Bank, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Rozsivalova, P $u Hospital Pharmacy, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Bekova, L $u Hospital Pharmacy, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Duchacova, Z W $u Hospital Pharmacy, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Belada, D $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Radocha, J $u 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Czech Republic
700    1_
$a Mericka, P $u Tissue Bank, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Fuller, B $u Division of Surgery, UCL and Royal Free London NHS Trust, London NW3 2QG, UK
773    0_
$w MED00008393 $t Cryo-letters $x 0143-2044 $g Roč. 44, č. 3 (2023), s. 123-133
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37883165 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094526 $b ABA008
999    __
$a ok $b bmc $g 2049744 $s 1210993
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 44 $c 3 $d 123-133 $e - $i 0143-2044 $m Cryo-letters $n Cryo Letters $x MED00008393
LZP    __
$a Pubmed-20240109
Back

Find record

Citation metrics

Archiving options